Completion of Chronic Hepatitis C Virus Treatment in Interferon-Induced Major Depressive Disorder with Psychotic Features
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Interferon (IFN)-associated psychiatric disorders can be managed without interruption to hepatitis C virus (HCV) treatment. The limited number of cases in the literature reporting psychotic depression as an adverse drug reaction to IFN resulted in discontinuation of HCV therapy. The author reports a case of a 49 year-old man with chronic HCV genotype 1a treated with pegylated interferon-alpha and ribavirin developing major depressive disorder with psychotic features. The patient was successfully treated with both an antidepressant and antipsychotic for this suspected IFN-associated adverse drug effect while continuing 12 months of uninterrupted HCV treatment and subsequently achieving sustained hepatitis C virological response. Although IFN can cause distressing psychiatric disturbances, appropriate treatment with psychotropic agents and careful monitoring allows patients to be maintained on a full course of HCV treatment.
Abstract
Interferon (IFN)-associated psychiatric disorders can be managed without interruption to hepatitis C virus (HCV) treatment. The limited number of cases in the literature reporting psychotic depression as an adverse drug reaction to IFN resulted in discontinuation of HCV therapy. The author reports a case of a 49 year-old man with chronic HCV genotype 1a treated with pegylated interferon-alpha and ribavirin developing major depressive disorder with psychotic features. The patient was successfully treated with both an antidepressant and antipsychotic for this suspected IFN-associated adverse drug effect while continuing 12 months of uninterrupted HCV treatment and subsequently achieving sustained hepatitis C virological response. Although IFN can cause distressing psychiatric disturbances, appropriate treatment with psychotropic agents and careful monitoring allows patients to be maintained on a full course of HCV treatment.
참고문헌 (16)
- WHO, "Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Renault PF, "Psychiatric complications of long-term interferon alpha therapy", Arch Intern Med, 147, pp.1577~1580 (1987)
- McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group", N Engl J Med, 339, pp.1485~1492 (1998)
- Martin-Santos R, "De novo depression and anxiety disorders and influence on adherence during peginterferon-alpfa-2a and ribavirin treatment in patients with hepatitis C", Aliment Pharmacol Ther, 27, pp.257~265 (2008)
- Onyike CU, "Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin", Am J Psychiatry, 161, pp.429~435 (2004)
- Garcia-Parés G, "Psychosis induced by interferon-alpha", Psychosomatics, 43, pp.428~429 (2002)
- Tamam L, "Psychosis associated with interferon alfa therapy for chronic hepatitis B", Ann Pharmacother, 37, pp.384~387 (2003)
- Hoffman RG, "Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV", Psychosomatics, 44, pp.417~420 (2003)
- Ademmer K, "Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C", Psychosomatics, 42, pp.365~367 (2001)
- Spitzer RL, "Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire", JAMA, 282, pp.1737~1744 (1999)
- Kalyoncu OA, "Beyazyurek M. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser", J Psychopharmacol, 19, pp.102~105 (2005)
- Sockalingam S, "Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment", Int Clin Psychopharmacol, 20, pp.289~290 (2005)
- Quarantini LC, "Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report", Braz J Infect Dis, 10, pp.406~407 (2006)
- Menkes DB, "MacDonald JA. Interferons, serotonin, and neurotoxicity", Psychol Med, 30, pp.259~268 (2000)
- Silverman BC, "Interferon-induced psychosis as a “psychiatric contraindication” to hepatitis C treatment: a review and case-based discussion", Psychosomatics, 51, pp.1~7 (2010)